Does Dr. NAGLA ABDEL KARIM have financial conflicts of interest?

Dr. NAGLA ABDEL KARIM (MD) has received a total of $99,833 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $99,833 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. NAGLA ABDEL KARIM?

According to CMS Open Payments data, Dr. NAGLA ABDEL KARIM received funding from REGENERON HEALTHCARE SOLUTIONS ($31,779), GENZYME CORPORATION ($14,225), and JAZZ PHARMACEUTICALS ($10,555).

Does Dr. NAGLA ABDEL KARIM receive research grants or speaking fees?

Dr. NAGLA ABDEL KARIM has received $99,833 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. NAGLA ABDEL KARIM

MDReal-Time Hydrated

Specialty: Internal Medicine, Medical Oncology

Practice Location: FAIRFAX, VA 22031

NPI Number: 1881805166

LIFETIME INDUSTRY VALUE

$99,833

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABDEL KARIM is a verified Internal Medicine, Medical Oncology practitioner based in FAIRFAX, VA.

Between 2021 and 2024, Dr. ABDEL KARIM had an overall industry promotional and research financial footprint of $99,833 as recorded in the federal CMS Open Payments database.

$99,833 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDEL KARIM's primary funding source is REGENERON HEALTHCARE SOLUTIONS, which accounts for $31,779 (representing 31.8% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

REGENERON HEALTHCARE SOLUTIONS

Rank 1

$31,779

31.8%

GENZYME CORPORATION

Rank 2

$14,225

14.2%

JAZZ PHARMACEUTICALS

Rank 3

$10,555

10.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.